Physician profile
Kader T Abdelerahman
NPI 1003058157
$606,569.19
in general payments reported to CMS, 2019-2025
63 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $58K · 2021: $107K · 2022: $94K · 2023: $85K · 2024: $87K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $187K · Consulting Fee: $44K · Food and Beverage: $27K · Travel and Lodging: $14K · Education: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $186,643.50 |
| Consulting Fee | $43,972.50 |
| Food and Beverage | $26,697.17 |
| Travel and Lodging | $14,001.80 |
| Education | $1,412.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $159,465.19 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $126,532.20 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Neurocrine Biosciences, INC. | $108,387.00 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $46,492.65 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Genzyme Corporation | $43,147.58 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $35,034.54 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Allergan, INC. | $24,568.46 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $20,123.55 | 2020-2021 | |
| Amgen INC. | $8,970.65 | 2019-2025 | Uplizna |
| Ucb, INC. | $6,220.68 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Argenx US, INC. | $5,628.05 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company Ltd. | $5,554.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,983.01 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $1,764.47 | 2020-2025 | Ongentys 50mg Capsules 30, Ongentys, Crexont |
| Alexion Pharmaceuticals, INC. | $1,547.30 | 2019-2025 | Ultomiris, Soliris |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,314.28 | 2019-2025 | Nuplazid |
| Pfizer INC. | $1,008.60 | 2019-2025 | |
| Genentech USA, INC. | $888.62 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $846.44 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Csl Behring | $625.91 | 2019-2025 | Hizentra, Privigen, Kcentra |
| Lundbeck LLC | $567.80 | 2020-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $473.61 | 2021-2025 | Xcopri |
| Eisai INC. | $439.25 | 2022-2025 | |
| Horizon Therapeutics Plc | $376.95 | 2021-2023 | Uplizna |
| Neurelis, INC. | $349.79 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $328.16 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $256.58 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $252.01 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $249.42 | 2025 | Rexulti |
| Genentech, INC. | $241.95 | 2023-2025 | Ocrevus, Enspryng |
| Acorda Therapeutics, INC | $233.59 | 2019-2023 | Inbrija |
| Tg Therapeutics, INC. | $226.51 | 2024-2025 | |
| Banner Life Sciences, LLC | $220.97 | 2023-2024 | |
| Janssen Biotech, INC. | $213.30 | 2025 | |
| Alnylam Pharmaceuticals INC. | $171.28 | 2022-2024 | Amvuttra |
| Springworks Therapeutics, INC. | $149.67 | 2025 | Gomekli |
| Ipsen Biopharmaceuticals, INC | $147.06 | 2024-2025 | Dysport |
| Averitas Pharma INC. | $137.33 | 2024-2025 | Qutenza |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $135.00 | 2022 | |
| Merz Pharmaceuticals, LLC | $117.25 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $116.37 | 2025 | Hyqvia |
| E.R. Squibb & Sons, L.L.C. | $110.93 | 2024 | Zeposia |
| W. L. Gore & Associates, INC. | $99.74 | 2022 | |
| Celgene Corporation | $88.04 | 2022-2023 | Zeposia |
| Upsher-Smith Laboratories LLC | $71.49 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $70.36 | 2024-2025 | Rexulti |
| Tanabe Pharma America, INC. | $63.06 | 2019-2023 | |
| Impel Pharmaceuticals INC. | $51.50 | 2023 | Trudhesa |
| Grifols USA, LLC | $47.92 | 2024 | Gamunex-C |
| Abbott Laboratories | $46.95 | 2022-2023 | Infinity |
| Vertical Pharmaceuticals, LLC | $46.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $44.86 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $44.12 | 2024-2025 | |
| Gt Medical Technologies, INC | $42.79 | 2025 | Gammatile |
| Impel Pharmaceuticals LLC | $40.13 | 2025 | Trudhesa |
| Ge Healthcare | $36.39 | 2025 | |
| Kedrion Biopharma, INC. | $35.50 | 2024 | Koate, Gammaked, Kedrab |
| Vanda Pharmaceuticals INC. | $34.78 | 2025 | Ponvory |
| Kyowa Kirin, INC. | $22.91 | 2024 | Nourianz |
| Portola Pharmaceuticals, LLC | $19.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Cycle Pharmaceuticals INC | $14.64 | 2025 | Bafiertam, Tascenso Odt |
| Intercept Pharmaceuticals, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kader Abdelerahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.